易華錄(300212.SZ):向不特定對象發行可轉債相關事項獲得中國華錄集團批覆
格隆匯1月11日丨易華錄(300212.SZ)公佈,2022年1月11日,公司收到中國華錄集團有限公司下發的《關於北京易華錄信息技術股份有限公司向不特定對象發行可轉換公司債券有關問題的批覆》,批覆主要內容如下:
一、原則同意公司向不特定對象發行不超過23.0124億元(含23.0124億元)可轉換公司債券的總體方案。
二、請公司高度重視,合理把握資本市場狀況,科學選擇發行時間窗口,妥善做好資金安排,提高募集資金使用效率,促進公司持續健康發展,維護國有股東合法權益。
三、請公司按照證券監管和國資監管的相關規定,認真做好信息披露等相關工作,嚴格規範操作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.